Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma

• Status: Completed
• Trial end date: 2018-05-02
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of the optimal dose for the efficacy in reduction of intraocular pressure and safety of PHP-201 ophthalmic solution in patients with normal tension glaucoma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: pH Pharma
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• 19 years and older, female and male

• IOP ≤21 mmHg

• Subject showing open angle finding, glaucomatous optic nerve damage and visual field defects

• BCVA ≥+0.2

Exclusion Criteria:

• Subject with the disease and surgery history that are not eligible to participate (acute closed angle glaucoma, narrow angle glaucoma, advanced glaucomatous loss, ocular trauma, eye surgery or laser surgery, unstable angina, myocardial infarction, uncontrolled hypertension and diabetes, etc)

• Subject who can't discontinue contact lenses

• Subject who can't discontinue topical/systemic IOP lowering medication